DLH Holdings Corp. — Form 10-Q Summary
Business context and reporting period. This filing covers the fiscal quarter and six months ended March 31, 2020. DLH provides technology-enabled health and human services, deriving essentially all revenue from U.S. federal agencies. The Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) are its largest customers. Results include revenue from Social & Scientific Systems (S3), whose acquisition contributed materially to growth.
Financial results
| Metric | Three months ended March 31 | Six months ended March 31 |
|---|---|---|
| Revenue | $54.8 million; up 62.3% year over year | $107.0 million; up 58.6% |
| Operating income and margin | $3.8 million; 7.0% | $7.0 million; 6.5% |
| Net income | $2.1 million; diluted EPS $0.16 | $3.6 million; diluted EPS $0.28 |
| Net margin | 3.7% | 3.4% |
| EBITDA, non-GAAP | $5.6 million | $10.6 million |
Cash flow and liquidity. Six-month operating cash flow was $0.662 million, versus $6.779 million a year earlier; the decline was mainly attributed to an $11.7 million increase in accounts receivable, partly associated with financial-system integration. Cash was $1.124 million at March 31. The company reported $21.3 million of available revolver capacity, subject to borrowing conditions, and said planned operating cash flow should support operations for 12 months. MD&A separately describes six-month operating cash generation as $1 million; the statements report $0.662 million.
Debt and obligations. At March 31, the company had $53.0 million of term-loan principal and $2.0 million outstanding on its revolver; the revolver balance was paid the following month. Net term debt carrying value was $50.9 million. Both facilities mature June 2024 and are secured by substantially all company assets. Management reported covenant compliance. Operating lease liabilities totaled $23.4 million.
Changes versus prior comparable periods
- Quarterly revenue increased $21.0 million; six-month revenue increased $39.5 million. Management attributed the increases primarily to S3, contributing approximately $18.7 million in the quarter and $35.9 million over six months, as well as growth in legacy contracts.
- Net income rose to $2.1 million from $1.3 million for the quarter and to $3.6 million from $3.0 million for six months. Six-month operating margin declined to 6.5% from 7.2%, while quarterly operating margin was broadly stable at 7.0% versus 6.9%.
- Higher depreciation and amortization reflected amortization of S3 acquired intangible assets. Interest expense also rose, which management attributed to acquisition financing.
- HHS represented 47% of six-month revenue, up from 31%; VA represented 46%, down from 67%. Together, these agencies accounted for 93% of revenue.
- Adoption of lease accounting standard ASC 842 added $22.8 million of right-of-use assets and $23.4 million of lease liabilities at March 31. The company also recognized a $0.1 million gain on a lease modification. The company stated that the presentation reclassification of certain indirect costs did not change previously reported earnings.
Outlook, risks, and unusual items
- Management outlook: DLH said it did not expect COVID-19 to have a material impact in fiscal 2020, citing essential services, remote work, and continued contract execution. It anticipated increased operating cash flow in fiscal Q3. These are expectations, not guarantees; no formal earnings or revenue guidance was provided.
- COVID-19 risks: Potential impacts include reduced demand or changed federal spending priorities, delayed or terminated work, employee and facility disruptions, travel restrictions, and increased cybersecurity exposure from remote work. Management noted minor service delays and the possibility of disruptions at pharmacy distribution centers.
- Contract renewals: Nine VA pharmacy contracts, representing about $27.8 million of six-month revenue, were operating under extensions through October 2020; the related procurement was canceled and the government had not announced a new strategy. Seven VA logistics contracts, representing about $21.8 million of six-month revenue, were extended through June 2021 and were subject to a renewal procurement. The HHS Head Start contract, which generated $18.7 million in six-month revenue, was extended through August 2020; an RFP was expected in fiscal 2020.
- Backlog: Total backlog was approximately $426.4 million at March 31, including $106.0 million funded and $320.3 million unfunded. Backlog depends on contract performance and awards and is not assured revenue.
- Other exposures: A $36 million interest-rate swap hedged part of variable-rate debt; management estimated a 1% LIBOR increase would raise annual interest expense by less than $0.2 million. The company disclosed ordinary-course claims but no litigation it believed likely to materially harm results, financial position, or cash flows. No goodwill impairment was recorded; future contract losses or other adverse business changes could affect goodwill valuation.
Important facts for investors to verify
- Progress and award timing for the VA pharmacy and logistics procurements and the HHS Head Start recompete or extension.
- Whether the large receivables and contract-asset balance—$34.9 million and $10.2 million, respectively—convert to cash as management expects.
- COVID-19 effects on service delivery, employee safety, customer demand, and federal budgets, including any disruption at distribution facilities.
- Ongoing customer concentration, debt covenant compliance, and the terms and availability of revolver borrowings.
- The difference between reported operating cash flow of $0.662 million and MD&A’s rounded $1 million description.